search
Back to results

Evaluation of Magnetic Fields to Treat Fibromyalgia

Primary Purpose

Fibromyalgia

Status
Completed
Phase
Phase 2
Locations
Study Type
Interventional
Intervention
magnetic therapy protocol A
magnetic therapy Protocol B
placebo therapy
Sponsored by
pico-tesla Magnetic Therapies, LLC
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Fibromyalgia focused on measuring Fibromyalgia, Pain associated with Fibromyalgia

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Current diagnosis of fibromyalgia made by the study Principal Investigator (PI) according to the American College of Rheumatology 1990 Criteria for the Classification of Fibromyalgia.
  • Rating of current Degree of Pain on the 0-10 Numeric Pain Intensity Scale of 4 or greater.
  • Subject's use of pain relief medication(s) has been stable over the past 30 days, and subject is willing and able to maintain pre-existing use of pain relief medication(s) as his or her sole pain relief medication use, as needed, throughout study participation.
  • Subject's use of insomnia medication(s) has been stable over the past 30 days, and subject is willing and able to maintain this existing use of insomnia medication(s) as his or her sole insomnia relief medication(s), as needed, throughout study participation.
  • Subject has been on current (or no) medication regimen, unchanged for at least 30 days prior to study enrollment, and is willing and able to maintain that regular medication regimen, unchanged, throughout study participation.
  • Willing and able to refrain from use of tender point injections throughout study participation.
  • Willing and able to abstain from partaking in other/new treatments to improve fibromyalgia symptoms during study participation.
  • Adequate contraceptive measures for female subjects. > 18 years of age or older.
  • Male or female.

Exclusion Criteria:

  • Any factors that might prevent the subject from completing a full course of therapy with the Resonator™ device, or from attending any of the scheduled study visits, or from completing any of the study measures.
  • Subject suffers from co-existent chronic pain condition(s) of non-fibromyalgia origin, such as osteoarthritis, low back pain, neck pain, painful diabetic neuropathy and postherpetic neuropathic pain, that cannot be distinguished in severity and/or in type/sensation of pain from the pain originating from the subject's condition of fibromyalgia.
  • Any other significant comorbidities that might impact the ability to evaluate the subject's satisfaction of the ACR 1990 Criteria for the Classification of Fibromyalgia, or for the subject to complete any of the study assessment tools.
  • Tender point injections received within the prior one month.
  • Current or past history of major psychiatric disturbance (e.g., schizophrenia, bipolar disorder, substance abuse).
  • Known inflammatory rheumatic disease.
  • Epilepsy/history of seizures/taking medication for epilepsy.
  • HIV and other autoimmune disorders.
  • Active cancer or treatment for cancer within last 6 months.
  • Active infection(s).
  • History of ECT
  • Uncontrolled Hypertension.
  • Advanced Pulmonary Disease.
  • Unstable cardiac disease.
  • Prosthetics or implants comprised of ferrous metals.
  • Pacemakers, vagus nerve stimulators, or other functional electrical stimulators such as those commonly used for pain.
  • Consumption of more than 21 alcoholic drinks per week.
  • Pregnant, breast feeding, or planning pregnancy prior to end of study participation.
  • Developmental disability or other cognitive impairment that would in the judgment of the PI impair adequate comprehension of the informed consent form or complete any of the study-related activities.
  • Worker's compensation, receipt of disability or present/past litigation for monetary compensation pertaining to subject's fibromyalgia condition.
  • Participation in other research within 30 days of study enrollment.

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm 3

    Arm Type

    Active Comparator

    Active Comparator

    Placebo Comparator

    Arm Label

    Resonator Protocol A

    Resonator Protocol B

    Inactive Resonator

    Arm Description

    Application of magnetic fields using the Resonator device Protocol B

    Outcomes

    Primary Outcome Measures

    Mean Change in 3-recording Average of the Subjects Daily Pain Rating on the 0-10 Numeric Pain Intensity Scale.
    Minimum scale value is '0' which represents 'no pain at all' and is the best outcome. Maximum scale value is '10 which represents the 'worst pain imaginable' and is the worse outcome.

    Secondary Outcome Measures

    Full Information

    First Posted
    December 14, 2010
    Last Updated
    June 6, 2011
    Sponsor
    pico-tesla Magnetic Therapies, LLC
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT01262131
    Brief Title
    Evaluation of Magnetic Fields to Treat Fibromyalgia
    Official Title
    A Randomized, Double-blind, Placebo-controlled Evaluation of the Application of Magnetic Fields Using the Resonator Device for the Treatment of Fibromyalgia: Pilot Study Protocol
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    June 2011
    Overall Recruitment Status
    Completed
    Study Start Date
    December 2010 (undefined)
    Primary Completion Date
    May 2011 (Actual)
    Study Completion Date
    May 2011 (Actual)

    3. Sponsor/Collaborators

    Name of the Sponsor
    pico-tesla Magnetic Therapies, LLC

    4. Oversight

    Data Monitoring Committee
    No

    5. Study Description

    Brief Summary
    The purpose of this study is to see if a device called the Resonator can help to reduce pain and improve aspects of health and quality of life for people with fibromyalgia.
    Detailed Description
    The purpose of this pilot study is to assess the efficacy of the Resonator device as an adjunctive therapy to reducing pain and improving aspects of health and quality of life that are relevant to individuals with fibromyalgia.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Fibromyalgia
    Keywords
    Fibromyalgia, Pain associated with Fibromyalgia

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Phase 2
    Interventional Study Model
    Parallel Assignment
    Masking
    ParticipantInvestigatorOutcomes Assessor
    Allocation
    Randomized
    Enrollment
    13 (Actual)

    8. Arms, Groups, and Interventions

    Arm Title
    Resonator Protocol A
    Arm Type
    Active Comparator
    Arm Title
    Resonator Protocol B
    Arm Type
    Active Comparator
    Arm Description
    Application of magnetic fields using the Resonator device Protocol B
    Arm Title
    Inactive Resonator
    Arm Type
    Placebo Comparator
    Intervention Type
    Device
    Intervention Name(s)
    magnetic therapy protocol A
    Intervention Description
    Application of magnetic fields using the Resonator device Protocol A
    Intervention Type
    Device
    Intervention Name(s)
    magnetic therapy Protocol B
    Intervention Description
    Application of magnetic fields using the Resonator device Protocol B
    Intervention Type
    Device
    Intervention Name(s)
    placebo therapy
    Intervention Description
    Application of inactive magnetic fields using the Resonator device
    Primary Outcome Measure Information:
    Title
    Mean Change in 3-recording Average of the Subjects Daily Pain Rating on the 0-10 Numeric Pain Intensity Scale.
    Description
    Minimum scale value is '0' which represents 'no pain at all' and is the best outcome. Maximum scale value is '10 which represents the 'worst pain imaginable' and is the worse outcome.
    Time Frame
    2 weeks (baseline to end of treatment)

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    18 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: Current diagnosis of fibromyalgia made by the study Principal Investigator (PI) according to the American College of Rheumatology 1990 Criteria for the Classification of Fibromyalgia. Rating of current Degree of Pain on the 0-10 Numeric Pain Intensity Scale of 4 or greater. Subject's use of pain relief medication(s) has been stable over the past 30 days, and subject is willing and able to maintain pre-existing use of pain relief medication(s) as his or her sole pain relief medication use, as needed, throughout study participation. Subject's use of insomnia medication(s) has been stable over the past 30 days, and subject is willing and able to maintain this existing use of insomnia medication(s) as his or her sole insomnia relief medication(s), as needed, throughout study participation. Subject has been on current (or no) medication regimen, unchanged for at least 30 days prior to study enrollment, and is willing and able to maintain that regular medication regimen, unchanged, throughout study participation. Willing and able to refrain from use of tender point injections throughout study participation. Willing and able to abstain from partaking in other/new treatments to improve fibromyalgia symptoms during study participation. Adequate contraceptive measures for female subjects. > 18 years of age or older. Male or female. Exclusion Criteria: Any factors that might prevent the subject from completing a full course of therapy with the Resonator™ device, or from attending any of the scheduled study visits, or from completing any of the study measures. Subject suffers from co-existent chronic pain condition(s) of non-fibromyalgia origin, such as osteoarthritis, low back pain, neck pain, painful diabetic neuropathy and postherpetic neuropathic pain, that cannot be distinguished in severity and/or in type/sensation of pain from the pain originating from the subject's condition of fibromyalgia. Any other significant comorbidities that might impact the ability to evaluate the subject's satisfaction of the ACR 1990 Criteria for the Classification of Fibromyalgia, or for the subject to complete any of the study assessment tools. Tender point injections received within the prior one month. Current or past history of major psychiatric disturbance (e.g., schizophrenia, bipolar disorder, substance abuse). Known inflammatory rheumatic disease. Epilepsy/history of seizures/taking medication for epilepsy. HIV and other autoimmune disorders. Active cancer or treatment for cancer within last 6 months. Active infection(s). History of ECT Uncontrolled Hypertension. Advanced Pulmonary Disease. Unstable cardiac disease. Prosthetics or implants comprised of ferrous metals. Pacemakers, vagus nerve stimulators, or other functional electrical stimulators such as those commonly used for pain. Consumption of more than 21 alcoholic drinks per week. Pregnant, breast feeding, or planning pregnancy prior to end of study participation. Developmental disability or other cognitive impairment that would in the judgment of the PI impair adequate comprehension of the informed consent form or complete any of the study-related activities. Worker's compensation, receipt of disability or present/past litigation for monetary compensation pertaining to subject's fibromyalgia condition. Participation in other research within 30 days of study enrollment.
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    Jerry I Jacobson, Ph.D, D.M.D.
    Official's Role
    Principal Investigator

    12. IPD Sharing Statement

    Learn more about this trial

    Evaluation of Magnetic Fields to Treat Fibromyalgia

    We'll reach out to this number within 24 hrs